Financial Daily from THE HINDU group of publications
Thursday, Feb 05, 2004

News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Corporate - Announcements
Markets - Stocks


Aurobindo Pharma allots warrants to promoters

Our Bureau

Hyderabad , Feb. 4

FOLLOWING the consent of shareholders at the extraordinary general meeting in November last, the board of directors of Aurobindo Pharma Ltd (APL), the city-based pharmaceutical major, at the meeting held on Wednesday, has allotted convertible share warrants to promoters.

The company informed the stock exchanges that the board has allotted 25 lakh warrants to the promoter, Mr P.V. Ramaprasad Reddy, at Rs 375 per warrant on payment of Rs 140 per warrant up-front. The balance amount of Rs 235 per warrant would be payable at the time of conversion of these warrants into equity shares of Rs 5 each of the company within the stipulated time as per the SEBI guidelines.

More Stories on : Announcements | Stocks | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Stories in this Section
Bio-Rad Labs launches new diagnostic kit for diabetes


PSL bags pipeline deal in Bangladesh
Aurobindo Pharma allots warrants to promoters
Indian Hotels mops up $150 m via foreign currency bonds
Reliance raises $250 m from overseas loans
Ashok Leyland to raise $100 m via bonds/GDRs
Lagaan and Bawarchi — recipes for India Inc
Amendments moved at L&T EGM defeated
Century Plyboards plans laminates unit
Orchid drug cleared for export to Europe
Sangeet Cinema in pact with Singapore cos for Cineplex
`Entry into regulated markets will be our focus'
Honda cars Jan sales up 90% at 2,781 units
Tata Motors Jan sales up 32 pc
Hyundai Jan sales at 17,035 units, up 66 pc



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line